by stock prJanuary 9, 2012
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) recently provided a clinical update on its lead investigational therapeutic, lomitapide. Aegerion reported that the 78-week data from its pivotal Phase II
FREE Daily Stock Alerts From Stock-PR.com
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) recently provided a clinical update on its lead investigational therapeutic, lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial are consistent with data previously reported at the 26- and 56-week time points. The Phase III study was a single-arm, open label trial, designed to evaluate the efficacy and long-term safety of lomitapide for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks.
“We expect to submit our applications containing the 56-week data to the FDA and EMA this quarter and continue to build our commercial organization in preparation for our anticipated launch,” stated Marc D. Beer, Chief Executive Officer.
Read full article at: http://stock-pr.com/21158/stock-alerts/aegr-crwe-ceg-dte-sgl-stock-market-update-from-stockprcom/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer). Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
News Source: http://www.free-press-release.com/news-aegr-crwe-ceg-dte-sgl-stock-market-update-from-stock-pr-com-1326108420.html
In Her Latest Webinar, Sue Clement, Marketing Strategist and Referral Expert Shares The 3 Key Roadblocks That Keep Business Owners And Solo Professionals From Getting More Clients.
Angelina Jolie says that she has had a preventive double mastectomy after learning she carried a gene that made it extremely likely she would get breast cancer.